On January 10, 2020, the Theralight, Inc. company, owner of the Dualight system, was acquired by TheraLight, LLC, owner of the world renowned TheraLight 360 full body photobiomodulation system. This acquisition includes all intellectual property: patents, trademarks, FDA clearances and product specifications specifically for the Dualight product. On June 30, 2020, TheraLight, LLC publicly announced the acquisition and plans to launch a new version of the Dualight system called the DuaLight 308. This new version was made available for purchase on September 1, 2020. The DuaLight brand operates under parent company Humanwise Labs, Inc., who also owns and operates TheraLight, LLC.
Why Choose us?
Our system provides many advantages and options in one machine.
For the last 30 years, laser and light therapy systems have become the top choice for phototherapy. The DuaLight system combines the power of light illuminated from icetron lamps with the design to create the perfect, hands-free phototherapy system.
The targeted phototherapy instrumentation and method are patented in the U.S.A. (No. 6,413,268 issued 2 July, 2002). This patent includes the method of using selected lamp-based radiation, which allows for the treatment of contiguous skin segments. It is the only system in the world that provides the Physician with the option of using either targeted UVB or UVA.
An additional patent (No. 6,447,537) for Theralight machines establishes a platform for the development of future, innovative phototherapy products.
Instrumentation patents are pending worldwide.
These patents are a demonstration of the company’s long-term commitment to develop products that are based upon sound scientific principles. It is the company’s ambition to understand the underlying Photobiology of the diseases its products will treat.
The DuaLight Targeted Photothearpy is FDA cleared for the treatment of psoriasis, vitiligo, and other autoimmune skin conditions.
FDA K024020 Intended Use:
The TheraLight UV120-2 UVA / UVB Phototherapy System is intended for use in PUVA photochemistry and UVB phototherapy for the treatment of psoriasis, vitiligo, atopic dermatitis (eczema), and seborrheic dermatitis. In addition, the System UVB channel is indicated for the treatment of leukoderma.
K022165 Intended Use:
The TheraLight UV120-2 UVA I UVB Phototherapy System is indicated for use in PUVA photochemistry and UVB phototherapy for the treatment of psoriasis, vitiligo, atopic dermatitis (eczema), and seborrheic dermatitis.
Product: DUALight Targeted UVA / UVB Phototherapy System
The DuaLight Company is also FDA Registered.